Eli Lilly reported a remarkable 48% revenue growth driven by strong sales of Mounjaro and Zepbound, yet its stock price remains nearly flat this year. Despite recent stock volatility due to price cuts, acquisition charges, and competition concerns, analysts see potential for a 15-30% upside, with some predicting shares could reach $1,500 by the end of 2027. Key catalysts include FDA approvals for new drugs and ongoing positive earnings revisions. The main risks are regulatory setbacks or increased competition from Novo Nordisk.
Eli Lilly's shares trade at USD 1,165.02 on Pluang as of Sep 22, 2026 00:41 WIB, showing a modest 1.11% gain in the last day. Despite the stock's nearly flat performance this year, its market cap remains substantial at $1.03 trillion, reflecting strong investor interest. The article highlights potential upside and risks, while on Pluang, the stock holds a dividend yield of 0.6% and a typical hold time of 93 days, indicating steady investor engagement.
Since Medicare began covering obesity drugs in July, 700,000 new seniors have started GLP-1 treatments, with 70% using Eli Lilly's medicines. The coverage, part of a temporary "Bridge" program, allows eligible seniors to access weight loss drugs for ...
Novo Nordisk's shares fell over 7% after the company announced long-term targets that failed to reassure investors about competition in the weight-loss drug market. The Danish drugmaker plans to launch multiple blockbuster drugs by 2030 and aims for ...
Nvidia and Eli Lilly both exceeded earnings expectations, but Nvidia's AI-driven data center growth offers a stronger long-term investment opportunity. Nvidia posted $96.22 billion in revenue, driven by AI infrastructure demand and supply constraints...
Novo Nordisk's stock fell 7% following its capital markets day where it outlined a growth plan that aligns with industry peers rather than exceeding them, signaling slower future growth. The company highlighted the upcoming loss of U.S. patent exclus...
Eli Lilly will present mid-stage trial results for eloraTZP, a two-drug obesity treatment, on September 30. The data will show if the combo offers significantly better weight loss and tolerability than tirzepatide alone, crucial for sustaining the co...
